These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 11977101)
1. Pharmacokinetics and tissue distribution of a new partricin A derivative (N-dimethylaminoacetyl-partricin A 2-dimethylaminoethylamide diaspartate) in mice. Rimaroli C; Bonabello A; Sala P; Bruzzese T J Pharm Sci; 2002 May; 91(5):1252-8. PubMed ID: 11977101 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a new derivative of partricin A (SPA-S-753) in rodents. Galmozzi MR; Bruzzese T; Buffa G; Bonabello A Chemotherapy; 2000; 46(3):153-9. PubMed ID: 10765028 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics in rats of n-dimethylaminoacetyl-partricin a 2-dimethylaminoethylamide diascorbate (spk-843). Bruzzese T; Galmozzi MR; Buffa G; Sala P; Bonabello A Chemotherapy; 2001; 47(2):77-85. PubMed ID: 11173807 [TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of three preparations of the new antifungal SPK-843. Bruzzese T; Galmozzi MR; Ferrari VM; Sala P; Bonabello A Chemotherapy; 2001 Dec; 47(6):387-95. PubMed ID: 11786653 [TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro antifungal activity of the polyene derivative SPA-S-753 against encapsulated form of Cryptococcus neoformans. Strippoli V; D'Auria FD; Simonetti N; Basti D; Bruzzese T Infection; 1997; 25(1):27-31. PubMed ID: 9039534 [TBL] [Abstract][Full Text] [Related]
6. Potent antifungal effects of a new derivative of partricin A in a murine model of cerebral cryptococcosis. Luna T; Mazzolla R; Romanò G; Blasi E Antimicrob Agents Chemother; 1997 Mar; 41(3):706-8. PubMed ID: 9056019 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system. Segarra I; Movshin DA; Zarif L J Pharm Sci; 2002 Aug; 91(8):1827-37. PubMed ID: 12115810 [TBL] [Abstract][Full Text] [Related]
8. Overview of SPA-S-843 in vitro activity against filamentous fungi. Rimaroli C; Bruzzese T Chemotherapy; 2000; 46(1):28-35. PubMed ID: 10601795 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of the partricin derivative SPA-S-753 against systemic murine candidosis. Clemons KV; Stevens DA J Antimicrob Chemother; 2001 Feb; 47(2):183-6. PubMed ID: 11157903 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Andes D; Safdar N; Marchillo K; Conklin R Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of a polyene antifungal agent, liposomal amphotericin B (L-AMB), in a severely burned patient. Sasaki J; Matsumoto K; Fujishima S; Morita K; Hori S J Chemother; 2014 Oct; 26(5):312-4. PubMed ID: 24070023 [No Abstract] [Full Text] [Related]
12. Hepatobiliary disposition of liposomal amphotericin B in the isolated perfused rat liver. Hong Y; Ramzan I; McLachlan AJ J Pharm Sci; 2005 Jan; 94(1):169-76. PubMed ID: 15761940 [TBL] [Abstract][Full Text] [Related]
13. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation. Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers. Bekersky I; Fielding RM; Dressler DE; Kline S; Buell DN; Walsh TJ J Clin Pharmacol; 2001 Sep; 41(9):963-71. PubMed ID: 11549101 [TBL] [Abstract][Full Text] [Related]
15. Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (AmBisome). Watanabe A; Matsumoto K; Igari H; Uesato M; Yoshida S; Nakamura Y; Morita K; Shibuya K; Matsubara H; Yoshino I; Kamei K Int J Infect Dis; 2010 Sep; 14 Suppl 3():e220-3. PubMed ID: 19959388 [TBL] [Abstract][Full Text] [Related]
16. Disposition of aerosolized liposomal amphotericin B. Lambros MP; Bourne DW; Abbas SA; Johnson DL J Pharm Sci; 1997 Sep; 86(9):1066-9. PubMed ID: 9294824 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. Gershkovich P; Wasan EK; Lin M; Sivak O; Leon CG; Clement JG; Wasan KM J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459 [TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models. Brime B; Frutos P; Bringas P; Nieto A; Ballesteros MP; Frutos G J Antimicrob Chemother; 2003 Jul; 52(1):103-9. PubMed ID: 12805269 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tissue distribution of rifametane, a new 3-azinomethyl-rifamycin derivative, in several animal species. Bruzzese T; Rimaroli C; Bonabello A; Mozzi G; Ajay S; Cooverj ND Arzneimittelforschung; 2000 Jan; 50(1):60-71. PubMed ID: 10683718 [TBL] [Abstract][Full Text] [Related]
20. A novel delivery system for amphotericin B with lipid nano-sphere (LNS). Fukui H; Koike T; Saheki A; Sonoke S; Seki J Int J Pharm; 2003 Oct; 265(1-2):37-45. PubMed ID: 14522116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]